Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 180Lymphoma 134Sarcoma 80Lymphoma, Large B-Cell, Diffuse 79Precursor Cell Lymphoblastic Leukemia-Lymphoma 70Hodgkin Disease 50Lymphoma, Non-Hodgkin 49Leukemia 41Burkitt Lymphoma 40Lymphoma, Mantle-Cell 37Lymphoma, Follicular 34Neuroblastoma 30Ovarian Neoplasms 26Multiple Myeloma 26Neoplasms 24Lymphoma, Large-Cell, Anaplastic 23Carcinoma, Hepatocellular 23Neoplasm Metastasis 20Lymphoma, Large-Cell, Immunoblastic 19Triple Negative Breast Neoplasms 18HIV Infections 18Urinary Bladder Neoplasms 15Acquired Immunodeficiency Syndrome 15Osteosarcoma 14Liposarcoma 14Leiomyosarcoma 13Histiocytoma, Malignant Fibrous 13Breast Neoplasms, Male 13Lymphoma, B-Cell, Marginal Zone 12Inflammatory Breast Neoplasms 12

Interventions

pegfilgrastim 1Taxes 1Platinum 1Paclitaxel 1Granulocyte Colony-Stimulating Factor 1Gefitinib 1Filgrastim 1Doxorubicin 1Cisplatin 1Carboplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Recurrent Uterine Corpus Carcinoma × Doxorubicin × Clear all
NCT00063999 2021-10-19

Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

GOG Foundation

Phase 3 Completed
1,381 enrolled 12 charts
Gynecologic

Recurrent Uterine Corpus Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡